Somatuline
Print

Somatuline® Autogel® & Somatuline® LA 30mg - lanreotide

Somatuline® Autogel® - lanreotide

Somatuline® LA 30mg - lanreotide

Description

Somatuline® Autogel® Lanreotide (I.N.N.) 60mg, 90mg or 120mg (as acetate), solution for injection in a pre-filled syringe, ready to be injected. White to pale yellow semi-solid formulation as a supersaturated solution.

Somatuline® LA Lanreotide (I.N.N) 30mg (as acetate), white powder for suspension for injection supplied with mannitol for reconstitution.

Active substance

lanreotide

Somatuline® Autogel® is indicated for:

  • The treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatment. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels and where possible to normalise these values.
  • The treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease (see section 5.1).
  • The treatment of symptoms associated with neuroendocrine (particularly carcinoid) tumours.

Somatuline® LA 30mg is indicated for:

  • The treatment of acromegaly when the circulating levels of growth hormone remain abnormal after surgery and/or radiotherapy.
  • The treatment of thyrotropic adenomas when the circulating level of thyroid stimulating hormone remains inappropriately high after surgery and/or radiotherapy.
  • The relief of symptoms associated with neuroendocrine (particularly carcinoid) tumours.